An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

March 6, 2020

Primary Completion Date

April 15, 2022

Study Completion Date

May 15, 2022

Conditions

Sjogren's Syndrome (SS)

Interventions

DRUG

Ravaglimab

Intravenous Injection

DRUG

Ravagalimab

Subcutaneous Injection

DRUG

Placebo

Intravenous Injection

DRUG

Placebo

Subcutaneous Injection

Trial Locations (1)

Universitair Medisch Centrum Utrecht /ID# 214029, Utrecht